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Abstract
Melatonin is a multifunctional hormone that has long been known for its antitumoral
effects. An advantage of the application of melatonin in cancer therapy is its ability to
differentially influence tumors from normal cells. In this review, the roles of
melatonin adjuvant therapy in human cancer are discussed. Combination of melatonin
with chemotherapy could provide synergistic antitumoral outcomes and resolve drug
resistance in affected patients. This combination reduces the dosage for chemother-
apeutic agents with the subsequent attenuation of side effects related to these drugs
on normal cells around tumor and on healthy organs. The combination therapy
increases the rate of survival and improves the quality of life in affected patients.
Cancer cell viability is reduced after application of the combinational melatonin
therapy. Melatonin does all these functions by adjusting the signals involved in cancer
progression, re‐establishing the dark/light circadian rhythm, and disrupting the redox
system for cancer cells. To achieve effective therapeutic outcomes, melatonin
concentration along with the time of incubation for this indoleamine needs to be
adjusted. Importantly, a special focus is required to be made on choosing an
appropriate chemotherapy agent for using in combination with melatonin. Because of
different sensitivities of cancer cells for melatonin combination therapy, cancer‐
specific targeted therapy is also needed to be considered. For this review, the
PubMed database was searched for relevant articles based on the quality of journals,
the novelty of articles published by the journals, and the number of citations per year
focusing only on human cancers.
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1 | INTRODUCTION
Multidrug resistance (MDR) is the cardinal reason for the low
efficacy of cancer chemotherapy (Fic et al., 2017). Chemotherapeutic
agents exert undesirable side effects on normal cells (Plaimee,
Weerapreeyakul, Barusrux, & Johns, 2015) and tissues (Lissoni, Barni
et al., 1999; Shen et al., 2017). Insufficient responses to cancer
chemotherapy also occur depending on variations among individuals
and also at more progressive stages of carcinogenesis (J. Wang et al.,
2013). In addition, chemotherapy only has a minor effect on the rate
of survival in patients (Lissoni, Chilelli, Villa, Cerizza, & Tancini, 2003).
To overcome deleterious issues with chemotherapeutic agents, the
focus of many reports has been on the strategy of using
a combination of chemotherapy with appropriate supplements
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(Plaimee et al., 2015) to overcome MDR (Pariente, Bejarano,
Rodríguez, Pariente, & Espino, 2017) and to achieve synergistic
antitumoral effects better than the application of single agents alone
(Casado‐Zapico et al., 2010). A combination therapy could also
provide therapeutic outcomes at considerably lower doses needed
for clinical efficacy (Sainz et al., 2003) and with a restricted spectrum
of adverse effects (Kontek & Nowicka, 2013). Biochemotherapeutic
strategies are promising for this context because they can regulate
cancer cell growth without causing a concomitant retardation of the
host anticancer immune defenses (Lissoni, Barni et al., 1999).
Melatonin (N‐acetyl‐5‐methoxytryptamine) is a pleiotropic and
multifunctioning indoleamine (J. Wang et al., 2013) produced from
pineal gland, and it is known for its antioxidant, pro‐oxidative
(Mortezaee & Khanlarkhani, 2017; Mortezaee, Khanlarkhani,
Beyer, & Zendedel, 2017), oncostatic (anticancer) (Plaimee et al.,
2015), and immunoregulatory (Koh et al., 2011) activities. There is
a high control over the circadian rhythm for melatonin synthesis
during carcinogenic processes (T. X. Vijayalaxmi, Thomas, Reiter, &
Herman, 2002). The activity of the pineal gland for production of
melatonin is reduced during cancer progression (Bartsch et al.,
1992). An inexpensive production of melatonin in a pharmacolo-
gically pure form (Reiter, Tan, Sainz, Mayo, & Lopez‐Burillo, 2002)
and a long shelf life for this indole (Sainz et al., 2003) are among
the benefits of the application of this hormone in cancer therapy.
Fortunately, no noticeable side effect has been reported for
melatonin, so it could be administered for cancer patients even at
high doses (Y. Wang et al., 2012); 1 g melatonin has been
administered for 30 d to human subjects, showing no adverse
effects (T. X. Vijayalaxmi et al., 2002).
What works against melatonin application is the fact that this
hormone is a naturally producing, nonpatentable molecule. There-
fore, interest in using this agent per se is low, in spite of its high
efficacy and low toxicity (Reiter et al., 2002). Application of
melatonin alone has also been reported in a number of studies to
be less or even ineffective for the reduction of some cancer markers,
while its administration as a pharmaceutical compound provides
other therapeutic activities (Gao et al., 2017) and cumulative
outcomes (J. H. Kim et al., 2012; Plaimee et al., 2015). Besides,
melatonin can mitigate toxicity and side effects induced by
chemotherapy agents on normal cells (Casado‐Zapico et al., 2010;
J.H. Kim et al., 2012), and it also provides higher tolerance to
chemotherapy in patients (Lissoni et al., 2003). Melatonin increases
the efficacy of chemotherapy drugs (Gao et al., 2017) and sensitizes
cancer cells to these agents (Gao et al., 2017; J. Wang et al., 2013).
Chemotherapeutic agents also have stimulatory effects on melatonin
concentration in the plasma (Kajdaniuk, Marek, & Kos‐Kudla, 2001).
Combination with melatonin has been applied so far for a number of
human tumors (Table 1).
More investigations are needed to shed light on the possible
mechanisms contributing to these additional potential virtues of
melatonin (J. Wang et al., 2013). Therefore, we aimed to review
the papers published from 1995 to 2018 regarding combination of
melatonin with chemotherapy to gain an understanding of the
possible potential roles of this adjuvant therapy in human cancer.
The criteria for choosing papers were the quality of the journals
and numbers of citations. Only studies on human cancer cell lines
and patients were selected for this literature. The tests and
methods used for the evaluation of the possible roles of melatonin
combination therapy have been shown in Table 2. All the data
presented in the article were collected from the cell lines obtained
from human cancers and studied in vitro. Exceptions to this
(studies on melatonin roles in the human body) have been
mentioned in the text.
2 | CELLULAR PROLIFERATION AND
VIABILITY
2.1 | Combination with melatonin increases
viability in normal cells
Melatonin has the capacity to act more specifically on cancer cells,
not on normal cells (J.H. Kim et al., 2012; Rodriguez‐Garcia et al.,
2013). Melatonin also attenuates chemotherapy‐related toxicity to
normal cells (Shen et al., 2017). Interestingly, the dose for melatonin
to exert toxicity in normal cells is much higher when it is used
in combination with chemotherapy than its application per se
(Granzotto, Rapozzi, Decorti, & Giraldi, 2001). There is a strong
evidence for low secretion of melatonin and higher incidence of
cancer development in patients under exposure to light during night‐
time (Y. Wang et al., 2012). In fact, melatonin reduces chemotherapy‐
induced toxicity on normal cells through re‐establishment in the
dark/light circadian rhythm (Lissoni, 2007).
2.2 | Combination with melatonin increases patient
survival
Melatonin combination increases the rate of survival for both
low (Lissoni, 2007; Lissoni, Barni et al., 1999) and advanced
(Lissoni, Paolorossi et al., 1997; Lissoni et al., 2003; Lissoni, Bolis,
Brivio, & Fumagalli, 2000; Lissoni, Mandalà, & Brivio, 2000) stages
of tumors. Improvement of the quality of life with limited side
effects is another benefit of combination therapy (Sookprasert
et al., 2014).
2.3 | Melatonin application per se depending on
duration of time and type of cancer could be
a target for inhibition of cancer cell survival
Exposure of cancer cells for 48 hr (Pariente, Bejarano, Espino et al.,
2017; Shen et al., 2017) and especially 72 hr (Y.‐X. Lu, Chen et al.,
2016; Margheri et al., 2012) to melatonin would probably be
appropriate for suppressing cancer cell viability. Cancer cells have
different responses to the viability inhibitory signals depending on
melatonin. For instance, the melatonin dosage that is deemed to be
too high to be effective for breast cancer (Margheri et al., 2012) is
appropriate for pancreatic cancer (Ju et al., 2016).
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TABLE 1 Chemotherapy drugs used in combination with melatonin for targeting human cancers
Cell lines
Drug and
effective dose
Effective dose of
melatonin
Incubation
time
Type of
cancer Ref.
SK‐LU‐1 CIS, 50 µM 1 and 2mM 48 hr Lung Plaimee et al. (2015)
SK‐OV‐3 CIS, 80 µM 2mM 24 hr Ovary J.H. Kim et al. (2012)
SW480 and LoVo, UA, 20 µM 1mM 48 hr Colon J. Wang et al. (2013)
HT‐29 Flavone, 150 µM 1mM – CRC Wenzel, Nickel, and Daniel (2005)
SW620 and LOVO 5‐FU, 30 μM 1mM 48 hr Colon Gao et al. (2017)
HeLa CIS, 20 µM
5‐FU, 1mM
DOX, no effective
1mM 24 hr Cervix Pariente, Pariente, Rodríguez, and
Espino (2016)
SK‐N‐MC Vincristine, 5 nM
Ifosfamide, 500 µM
1mM 48 and 72 hr Sarcoma Casado‐Zapico et al. (2010)
HL‐60 Puromycin, 1 µg/ml 1 mM 24 hr APL Koh et al. (2011)
HTOA and OVCAR‐3 CDDP, 0.5 µg/ml HTOA: 10−6 and 10−7M
OVCAR‐3: 10−9M
132 hr Ovary Futagami et al. (2001)
Patient Cisplatin, 20mg/m
etoposide, 100mg/m
– 7 days NSCLC Lissoni et al. (2003)
Cal‐27 and SCC‐9 Rapamycin, 20 nM 1mM 48 hr HNSCC Shen et al. (2017)
HT‐29 CRC and HeLa
Cervical cancer
5‐FU, 1mM 1mM 48 hr CRC and
cervix
Pariente, Bejarano, Espino,
Rodríguez, and Pariente (2017)
HT‐29 5‐FU, 1mM 1mM 48 and 72 hr CRC Pariente, Bejarano, Rodríguez
et al. (2017)
LoVo and LoVoDX Doxorubicin 0.1 and 1mM Colon Fic et al. (2017)
MeWo and Sk‐mel‐28 Fiestin 1 mM 48 hr Melanoma Yi et al. (2014)
MCF‐7 (breast) and
LoVo (colon)
Doxorubicin 100 pg/ml 1 hr Breast and
colon
Granzotto et al. (2001)
MCF‐7 Aminoglutethimide,
100 µM
1 nM 24 hr Breast Martínez‐Campa et al. (2005)
ESCC 5‐FU 1mM 72 hr Esophagus Y.‐X. Lu, Chen et al. (2016)
MiaPaCa‐2, AsPc‐1 and
Panc‐28
Gemcitabine, 5 µM 3mM 48 hr PDAC Ju et al. (2016)
H1299 and A549 BBR, 20 and 100 µM 1mM 48 hr Lung J.‐J. Lu, Fu et al. (2016)
H1975 Gefitinib, 1 µM 1mM 48 hr NSCLC Yun et al. (2014)
A549 and HT‐29 Irinotecan, 60 µM 50 μM 24 hr NSCLC
and CRC
Kontek and Nowicka (2013)
Caki TG, 50 nM 1mM 12 and 24 hr Kidney Min, Kim, Park, and Kwon (2012)
Caki Kahweol, 40 µM 1mM 24 hr Kidney Um, Park, and Kwon, 2011
Caki Oxaliplatin, 100 μm 1mMa 24 hr Kidney Um and Kwon (2010)
HT‐29 Proglumide, 1 mM
Lorglumide, 25 µM
Devazepide, 1 µM
1 and 2mM – Colon González‐Puga et al. (2005)
Patient Irinotecan (CPT‐11),
70mg/m2
20mg/kg 9 weeks CRC Cerea et al. (2003)
MCF‐7 Tamoxifen, 371 µg/ml 232 ng/ml 6 days Breast Wilson, Blask, and
Lemus‐Wilson (1992)
Note. 5‐FU: 5‐fluorouracil; APL, acute promyelocytic leukemia; atRA: all‐trans retinoic acid; BBR, berberine; CDDP: cis‐diamminedichloroplatinum;
CIS: cisplatin; CRC: colorectal cancer; DOX: doxorubicin; ESCC: esophageal squamous cell carcinoma; HNSCC: head and neck squamous cell carcinoma;
hrTNFα: human recombinant tumor necrosis factor α; NSCLC: non–small cell lung cancer; PDAC: pancreatic ductal adenocarcinoma; SST: somatostatin;
TG: thapsigargin; UA: ursolic acid.
aNegative effect on cancer remission.
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TABLE 2 Tests and methods used so far for evaluation of the roles for combination of melatonin and chemotherapy against cancer in human
Variable Methods of assessment Mechanism of action and assessment values Ref.
Apoptosis Annexin V/PI Distribution of phosphatidylserine (annexin V
staining) in the presence of propidium
iodide (PI) for evaluation of cellular
apoptotic stage
Annexin−/PI−: alive cells
Annexin+/PI−: early apoptotic cells
Annexin+/PI+: late apoptotic cells
Pariente, Bejarano, Espino et al. (2017);
Plaimee et al. (2015)
DAPI Evaluation of morphological changes in
chromatin (condensation and fragmentation
in the nucleus)
Plaimee et al. (2015); Shen et al. (2017)
Colorimetry and fluorimetry Activation in the caspase cascade Casado‐Zapico et al. (2010); Plaimee
et al. (2015)
FMKs FMKs are nontoxic cell permeable fluorescent
markers that attach to activated caspases in
apoptotic cells to inhibit them. Examples of
these inhibitors are DEVD‐FMK, IETD‐FMK,
and LEHD‐FMK for suppression of the
respective caspases 3, 8, and 9.
C.‐D. Kim, Cha, Li, and Cha (2015);
Pariente, Bejarano, Rodríguez et al. (2017)
Sub‐G1 arrest Cell arrest in the sub‐G1 phase of cell cycle
(accumulation of cells in this phase)
represents apoptotic cells having fractional
hypodiploid DNA content
Pariente, Bejarano, Rodríguez et al. (2017)
TUNEL DNA fragmentation J.H. Kim et al. (2012)
Electrophoresis Assessments of DNA for damages or
fragmentation is applicable through
electrophoresis. One of this methods is the
comet assay that is used for evaluation of
genotoxicity of chemotherapeutic agents.
Koyuncu, Gönel, Akdağ, and Yilmaz (2018);
Rodriguez‐Garcia et al. (2013); Shen
et al. (2017)
FACS Apoptotic cells J. Wang et al. (2013)
DΨm: cells are stained with rhodamine and
assessed by FACS
Loss of DΨm causes mitochondrial/intrinsic
apoptotic pathway
Y.‐X. Lu, Chen et al. (2016); Plaimee
et al. (2015)
IF Cyt‐c release J. Wang et al. (2013)
Hoechst Assessment of nuclear fragmentation, which is
a late marker for apoptosis. Nuclei in the
apoptotic cells contain a condensed chromatin
that is stained by Hoechst uniformly.
Korkmaz et al. (2009); Rodriguez‐Garcia et al.
(2013); Wenzel et al. (2005)
AO/EB Evaluation for the appearance of yellow cells
having red apoptotic bodies and condensed
chromatin
Gao et al. (2017)
LDH Release of LDH to the culture media indicates
cell death
Casado‐Zapico ; et al. (2010)
Western PARP cleavage Min et al. (2012)
ISEL Tumor cell death Margheri et al. (2012)
Viability and
growth
ChIP Binding of NF‐κβ on COX‐2 promoter J. Wang et al. (2013)
MTT Alive cells
MTS Alive cells Y.‐X. Lu, Chen et al. (2016)
XTT Alive cells J.H. Kim et al. (2012)
FACS Cell cycle analysis Koh et al. (2011)
Western NF‐κB/iNOS and COX‐2/iNOS/NF‐κB/p300
signaling
Gao et al. (2017)
PCNA and CCND1 known as proliferation
markers
Y.‐X. Lu, Chen et al. (2016)
Alamar Blue Alamar Blue (also called resazurin) is a poor
fluorescent dye that on reduction produces
resorufin that has high fluorescent activity
using for detection of viability
Csepregi et al. (2018); Futagami et al. (2001))
(Continues)
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2.4 | Combination with melatonin reduces viability
in cancer cells
Combination therapy with a melatonin dosage of 1mM would be
appropriate for targeting cell viability in most of the human cancer cell
lines, including leukemia (Koh et al., 2011), lung (Plaimee et al., 2015),
melanoma (Yi et al., 2014), head and neck squamous cell carcinoma
(HNSCC) (Shen et al., 2017), and colon (Gao et al., 2017; J. Wang et al.,
2013), whereas for ovarian cancer (J.H. Kim et al., 2012) higher
melatonin doses are required. This combination therapy reduces cell‐to‐
cell contact, colony formation (Gao et al., 2017; Yi et al., 2014), and the
IC50 of chemotherapeutic agents for targeting cancer (Gao et al., 2017;
J.‐J. Lu, Fu et al., 2016; J. Wang et al., 2013; Yi et al., 2014).
The sensitivity of cancer cells to different combination therapies
is different. For example, among the Cal‐27 and SCC‐9 cells of
HNSCC, the first cell type is more sensitive (Shen et al., 2017), and
the non–small cell lung cancer (NSCLC) cell line H1975 is more
sensitive than the HCC827 cells belonging to the same type of cancer
(Yun et al., 2014). This sensitivity is also dependent on the type of
chemotherapy. An example in this context is the CRC cell line HT‐29,
in which when cells are incubated for 48 (Pariente, Bejarano, Espino
et al., 2017; Pariente, Bejarano, Rodríguez et al, 2017) and 72 hr
(Pariente, Bejarano, Rodríguez et al., 2017), they show no responses
to melatonin combination therapy with cisplatin, while the viability of
the cells is reduced after exposure to combination therapy with 5‐FU.
Time duration positively influences the synergistic effects of
melatonin and chemotherapy for reducing the viability of cancer cells
(Casado‐Zapico et al., 2010), and it also reduces the dosage for
melatonin in combinational therapies (Granzotto et al., 2001).
TABLE 2 (Continued)
Variable Methods of assessment Mechanism of action and assessment values Ref.
TLVM Cell proliferation Margheri et al. (2012)
Electrophysiological patch clamp
analysis
Association between cell growth arrest with
changes in the membrane capacitance and ion
conductance
Margheri et al. (2012)
Oxidative
stress
Proxylfluorescamine and
camptothecin
Camptothecin generates O2
−
Proxylfluorescamine is a O2
− sensitive dye to
make it visualize fluorescently
Wenzel et al. (2005)
DCF‐DA A nonfluorescent dye that readily penetrates
cell membrane. When it enters the cell, it
becomes oxidized to form a fluorescent
product called DCF being proportional to
produce ROS inside the cellular milieu. DCF‐
DA could be detected by either fluorescence
microscopy or FACS analysis. H2‐DCF‐DA is
used for detection of H2O2
Y.‐X. Lu, Chen et al. (2016);
Pariente, Bejarano, Rodríguez et al. (2017);
Pariente et al. (2016); Shen et al. (2017); Um
and Kwon (2010)
Bioxytech LPO LPO markers MDA and 4‐HNE Shen et al. (2017)
Fluorimetry GSH and GSSG
Spectrophotometer GPx
JC‐1 JC‐1 dye is used for assessing mitochondrial
dysfunction by monitoring DΨm.
Mitochondrial dysfunction induced by
chemotherapy increases ROS production in
cancer cells. Red fluorescence indicates
normal membrane potential, and green
fluorescence indicates collapse of membrane
potential.
Margheri et al. (2012); Song et al. (2012)
XF24 flux analyzer Assessment of the O2 consumption rate as an
indicator for mitochondrial respiration.
Alteration in the O2 consumption is account
for mitochondrial dysfunction
Migration Scratch Scratch (also known as wound healing assay) is
the testing of possible ability to occupy the
scraped space by cell migration
Gao et al. (2017); J.‐J. Lu, Fu et al. (2016)
Western MMP‐9, β‐catein J.‐J. Lu, Fu et al. (2016)
Note. ChIP: chromatin immunoprecipitation; COX‐2: cyclooxygenase‐2; cyt‐c: cytochrome c; DCF‐DA: 2′,7′‐dichlorofluorescein diacetate;
DΨm: mitochondrial membrane potential; FACS: fluorescence ctivated cell sorting; GPx: glutathione peroxidase; GSH: glutathione; GSSG: glutathione
disulfide; ICC: immunocytochemistry; iNOS: inducible nitric oxide synthase; ISEL: in situ end labeling of nicked DNA; LDH: lactate dehydrogenase;
LPO: lipid peroxidation; MDA: malondialdehyde; 4‐HNE: 4‐hydroxy‐2‐nonenal; MDR: multidrug resistance; MMP: matrix metalloproteinase; MTT:
3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide; O2−: superoxide; PARP: poly ADP‐ribose polymerase 1; P‐gp: P‐glycoprotein; ROS: reactive
oxygen species; TLVM: time lapse video microscopy; XTT: 2,3‐bis (2‐methoxy‐4‐nitro‐5‐sulfophenyl)‐2‐tetrazolium 5‐carboxanilide.
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Responses from cancer cells to chemotherapy are also affected by
time duration. For example, cervical cancer HeLa cells show a
noticeable response to melatonin combination with cisplatin after
24 hr of exposure (Pariente et al., 2016), while the same cells show
more response to combination with 5‐FU after 48 hr (Pariente, Bejar-
ano, Espino et al., 2017).
Melatonin exerts inhibitory effects on the viability of cancer cells
through the MT3 receptor; therefore, reduction of the cytotoxic
effects of melatonin on cancer cells would be an outcome of MT3
blockade (Pariente, Bejarano, Espino et al., 2017). The inhibitors and
activators for melatonin receptors are listed in the Table 3.
3 | SURVIVAL ‐RELATED PATHWAYS AND
THE ROLES FOR COMBINATION
MELATONIN THERAPY
3.1 | Cyclooxygenase‐2/inducible nitric oxide
synthase/NF‐κB/p300 signaling
The multitasking protein cyclooxygenase‐2 (COX‐2) (J. Wang et al.,
2013) along with inducible nitric oxide synthase (iNOS) and its
product NO (Yi et al., 2014) is expressed in various human cancers,
and targeting these factors by combination melatonin therapy is a
way for retarding cancer cell survival (Gao et al., 2017; J.‐J. Lu, Fu
et al., 2016; J. Wang et al., 2013; Yi et al., 2014). Transcriptional
control over COX‐2 and iNOS is exerted through binding to co‐ and
transactivators such as p300 and NF‐κβ (Yi et al., 2014). NF‐κβ is
activated either by cancer cells or even by chemotherapy drugs, and
it is related to the mediation of the survival of cancer cells (Ju et al.,
2016) and their resistance to apoptosis (Rodriguez‐Garcia et al.,
2013). To be activated, NF‐κβ is required to be transferred from the
cytosol into the nucleus followed by further phosphorylation and
acetylation. Nuclear translocation and acetylation of NF‐κβ are
mediated by p‐IκBα and p300, respectively (Gao et al., 2017; J. Wang
et al., 2013; Yi et al., 2014). Combinational melatonin therapy is
capable of reducing p‐IKKα (Gao et al., 2017; J.‐J. Lu, Fu et al., 2016)
and p‐IκBα (Gao et al., 2017), so as to facilitate the cytosolic
translocation of p300 and NF‐κβ p50/p65 (J.‐J. Lu, Fu et al., 2016;
J. Wang et al., 2013; Yi et al., 2014). Moreover, combination therapy
probably inhibits the binding capacity of p50 and p65 onto the
COX‐2 (J. Wang et al., 2013; Yi et al., 2014) and iNOS (Gao et al.,
2017) promoter, decreases recruitment of p300 to this complex (i.e.,
p50/p65/COX‐2) (J. Wang et al., 2013; Yi et al., 2014), and further
reduces p65 phosphorylation (Gao et al., 2017) and acetylation (Yi
et al., 2014), eventually resulting in a blunt in the activation of the
COX‐2/iNOS/NF‐κB/p300 signaling.
3.2 | PI3K/AKT signaling
Phosphoinositide 3‐kinase (PI3K)/AKT signaling has been known to
involve in cancer cell proliferation and death (Gao et al., 2017).
Interestingly, chemotherapy drugs such as 5‐FU are found to
adversely increase AKT activity in cancer cells (Y.‐X. Lu, Chen et al.,
2016). On the other hand, combination therapy can partially
suppress the PI3K/AKT signaling and related proteins, including
110β, p85, and PDK1 (Gao et al., 2017).
3.3 | Feedback loop of mTOR/AKT
PT308 AKT is the mTORC1 phosphorylation site on AKT, and
pS473AKT is the mTORC2 phosphorylation site on AKT. MTORC2
activates pS473AKT that in turn activates mTORC1; this feedback
activation is a limitation for using mTORC1 inhibitors. The down-
stream target for mTORC1 is p‐S6. Reduction of p‐S6 and PT308 AKT
and increase of pS473AKT occurs after administration of chemother-
apy agents such as rapamycin. This negative feedback loop of AKT
phosphorylation could be effectively interrupted after combinational
melatonin therapy through specific harassment of pS473AKT (Shen
et al., 2017).
3.4 | ERK1/2/p90 ribosomal S6 kinase/heat shock
protein 27 pathway
ERK is a member of the mitogen‐activated protein kinase (MAPK)
family of proteins (C. Huang, Rajfur, Borchers, Schaller, & Jacobson,
2003) playing roles in various oncogenic events such as apoptosis
resistance and infinite proliferation (Y.‐X. Lu, Chen et al., 2016). p90
ribosomal S6 kinase (P90RSK) and heat shock protein 27 (HSP27) are
downstream proteins for ERK1/2 (J.H. Kim et al., 2012; Zoubeidi
et al., 2010), and MAPK phosphatase 3 (MKP3) is a known inhibitor
TABLE 3 Inhibitors and activators of melatonin receptors for targeting cancer chemo‐combination therapy with melatonin
Cancer type Compound and function
Involvement in the function mediated by chemo‐
combination therapy with melatonin Ref.
Cervical and colorectal Prazosin, MT3 blocker Reversing cytotoxicity and apoptosis Pariente,Bejarano,Espino
et al. (2017)4‐P‐PDOT, MT2 blocker No effect on cytotoxicity and apoptosis
Luzindole, MT1/MT2 blocker No effect on cytotoxicity and apoptosis
CLM, MT1/MT2 activator No effect on cytotoxicity and apoptosis
8‐M‐PDOT, MT2 activator No effect on cytotoxicity and apoptosis
PDAC Luzindole No effect on cytotoxicity and apoptosis Ju et al. (2016)
Renal cancer Luzindole No effect on ER stress‐induced apoptosis Min et al. (2012)
Lung cancer Luzindole No effect on cancer cell premature senescence Song et al. (2012)
Note. CLM: 6‐chloromelatonin; PDAC: pancreatic ductal adenocarcinoma; and ER: endoplasmic reticulum.
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for MAPK (Casado‐Zapico et al., 2010). P‐ERK expression is
adversely increased by chemotherapy agents such as 5‐FU (Y.‐X.
Lu, Chen et al., 2016). Melatonin plus cisplatin plays an inhibitory role
against the ERK1/2/p90RSK/HSP27 pathway through increase of
MKP3 protein, dephosphorization of p‐HSP27, ERK1/2, and RSK, and
reduction of HSP27 and p90RSK colocalization (J.H. Kim et al., 2012).
3.5 | Enhancer‐binding protein‐2β (AP‐2β)/human
telomerase reverse transcriptase signaling
The relationship between human telomerase reverse transcriptase
and its transcriptional regulator AP‐2β has been identified in cancer
cells, and it could be a target for melatonin combination therapy in
combating cancer cell proliferation (J.‐J. Lu, Fu et al., 2016).
3.6 | Acetylation and methylation in the gene
promoter
Melatonin combination reduces viability in cancer cells via acting on
promoter acetylation/methylation. Gene expression is increased by
acetylation and reduced by methylation (Yamanishi, Narazaki, & Asano,
2015). For example, melatonin combination through increase of
acetylation of the genes involved in clofarabine metabolism induces
sensitivity of leukemia cancer cells to this agent (Yamanishi et al., 2015).
3.7 | Ca2+channel‐mediated signal transduction
Ca2+ is involved in the promotion of cancer cell proliferation,
apoptosis, migration, and invasion. Ca2+ regulates the expressions
of cyclins A, D, and E. An abnormal increase in the intracellular Ca2+
triggers apoptosis (NavaneethaKrishnan, Rosales, & Lee, 2018;
Ouadid‐Ahidouch, Dhennin‐Duthille, Gautier, Sevestre, & Ahidouch,
2013). Mitochondrial Ca2+ overload activates mitochondrial perme-
ability transition pore, which in turn, induces ROS production
(NavaneethaKrishnan et al., 2018), and a positive reciprocal feedback
between mitochondrial fission with Ca2+ mediated by ROS con-
tributes to the promotion of autophagy and survival in cancer cells
(Q. Huang et al., 2017). Melatonin combination increases membrane
leakage to Ca2+ (Margheri et al., 2012) and reduces mitochondrial
fission mediators (Prieto‐Domínguez et al., 2016).
3.8 | Receptor‐mediated signaling
3.8.1 | Estrogen receptors
Women with estrogen receptor (ER)‐positive breast cancer have
lower nocturnal plasmatic concentration for melatonin than those
having ER‐negative breast cancer (Cos, Fern, & Mediavilla, 2003).
Melatonin acts as an antiestrogenic hormone indirectly through
downregulation of the hypothalamic–pituitary reproductive axis, or
directly through inhibition of ERs on cancer cells (NavaneethaKrish-
nan et al., 2018). Therefore, considering the degree of cancer
responsiveness to estrogen or the ERα/ERβ ratio affects the growth
inhibitory roles of melatonin used in combination therapies (Jawed
et al., 2007).
3.8.2 | Cholecystokinin receptors
There is a positive link between cancer growth with cholecystokinin
(CCK)‐A receptor (Gonzalez‐Puga et al., 2005; Ponnusamy et al.,
2016) that could be retarded using the combination of melatonin
with inhibitors for this receptor, including lorglumide and devazepide
(Gonzalez‐Puga et al., 2005).
3.9 | Notch receptors
Notch exerts an important role in a variety of cancers. For some
cancers, including hepatocellular carcinoma (HCC) and SCC (head
and neck, esophagus, and bladder), Notch signaling has a tumor‐
repressive function. Conversely, for cancers such as breast, brain,
NSCLC, and ovary, it is speculated that Notch acts as an oncogene
(Nowell & Radtke, 2017). Four transmembrane receptors for Notch
have been identified in mammals including Notch 1–4 (Al‐Hussaini,
Subramanyam, Reedijk, & Sridhar, 2011; Nowell & Radtke, 2017).
Melatonin combination inactivates Notch 1 receptor to combat
breast cancer growth (Margheri et al., 2012).
3.10 | Androgen receptor
Interaction between melatonin MT1 receptor with androgen recep-
tor (AR) induces regression of cancer cell proliferation. Therefore,
application of a combination of androgen depletion and melatonin
repletion would be a promising approach for AR‐dependent cancers
(Tam & Shiu, 2011). For example, melatonin combination therapy
induces colony regression (Rodriguez‐Garcia et al., 2013) and
apoptosis in the AR‐dependent prostate cancer cells, while it has
no effect on AR‐independent cells (Rodriguez‐Garcia et al., 2013).
4 | APOPTOSIS
Targeting apoptosis is a promising approach for cancer treatment
(Gao et al., 2017). Administration of melatonin per se induces
apoptosis in bone (Casado‐Zapico et al., 2010), HNSCC (Shen et al.,
2017), and cervical (Pariente, Bejarano, Espino et al., 2017) cancers,
but it has no effect on the apoptosis of a variety of cancers including
lung (Plaimee et al., 2015), leukemia (Koh et al., 2011), pancreas
(Rodriguez‐Garcia et al., 2013), and sarcoma (Casado‐Zapico et al.,
2010). The roles of melatonin in the apoptosis of colon cancer cells
are controversial, reported in one study to have no influence
(Wenzel et al., 2005), but in another report, an induction of apoptosis
was reported (Pariente, Bejarano, Espino et al., 2017). Melatonin
combination has either no effect (Um et al., 2011) or inhibitory role
for apoptosis of normal cells (J.H. Kim et al., 2012; Shen et al., 2017).
Combination melatonin therapy has no effect on apoptosis of HNSCC
cancer cells (Shen et al., 2017), while apoptosis of cancers such
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as pancreas (Rodriguez‐Garcia et al., 2013), colon (Pariente,
Bejarano, Espino et al., 2017; Pariente, Bejarano, Rodríguez 2017;
J. Wang et al., 2013; Wenzel et al., 2005), and HNSCC (Shen et al.,
2017) is positively influenced by this approach.
Combination therapy induces both extrinsic and intrinsic path-
ways of apoptosis (Casado‐Zapico et al., 2010). With an increase in
the pharmacologic concentration of melatonin, there is a rise in the
rate of apoptosis but a fall in the rate of necrosis in tumor cells
(Gonzalez‐Puga et al., 2005). For instance, combination with 1mM
melatonin has no effect on mitochondrial membrane potential (DΨm)
in lung cancer cells, while combination with 2mM melatonin induces
DΨm depolarization, which in turn results in release of cyt‐c from
mitochondria and further activation of caspase‐3 (Plaimee et al.,
2015). For leukemia, probably melatonin dosage and the type of
chemotherapy determine different traits for cancer responses to
combination therapy, as it has been attested that 50 µm melatonin
plus idarubicin reduces apoptosis in the cancer cells (Shen et al.,
2017), while 1mM melatonin plus puromycin increases apoptosis in
the cells (Koh et al., 2011).
Sensitivity of cancer cells to apoptotic signals from combination
therapy is different. For example, from two colon cancer cell lines
(i.e., SW620 and LoVo), SW620 cells are more sensitive to apoptotic
responses (Gao et al., 2017). In addition, evaluation of HT‐29 CRC
cells and HeLa cervical cancer cells has shown that the first cell type
is more sensitive to the combination therapy of melatonin with 5‐FU,
and the second cell type is more sensitive to the combination therapy
with cisplatin (Pariente, Bejarano, Espino et al., 2017).
The type of chemotherapy affects apoptotic responses to
combination therapy. Apoptotic responses from cervical cancer cells
to a combination of melatonin with cisplatin is high, with 5‐FU is
moderate, and with doxorubicin is negative (Pariente et al., 2016).
CRC, on the other hand, shows higher apoptotic responses to
combination therapy with 5‐FU, rather than with cisplatin
(Pariente, Bejarano, Espino et al., 2017; Pariente, Bejarano, Rodrí-
guez et al., 2017). Time duration is also an important criterion for
determining apoptotic fate. For example, CRC cells positively
respond to early apoptosis induced by melatonin combination with
cisplatin for 24 hr (Pariente, Bejarano, Espino et al., 2017). Longer
time duration (48 hr), however, is not effective for such responses
(Pariente, Bejarano, Rodríguez et al., 2017).
Reduction of telomerase activity by melatonin combination
therapy is a possible approach for inducing apoptotic cancer cell
death, which is dependent on the type of cancer cell. For instance,
combination with CDPP can reduce this activity in OVCAR‐3 rather
than in HTOA ovarian cancer cells (Futagami, Sato, Sakamoto,
Yokoyama, & Saito, 2001). Apoptotic responses to combination
melatonin therapy are MT3 dependent. An MT3‐blocker prazosin
inhibits both early and late apoptosis in cancer cells (Pariente, Bejar-
ano, Espino et al., 2017).
Apoptosis and mitophagy are two interrelated processes in
cancer. It seems that early induction of mitophagy facilitates
apoptotic cell death in tumor cells through excessive mitochondrial
removal, while its chronic induction in cancer cells stimulates cell
survival through allowing cell adaptation to stress (Shen et al., 2017).
Melatonin combination increases mitophagy mediators in early hours
of administration followed by their attenuation (Prieto‐Domínguez
et al., 2016), so modulation of mitophagy could be another approach
for combination therapy in targeting apoptosis resistance in cancer
cells (Prieto‐Domínguez et al., 2016).
Apoptosis and endoplasmic reticulum (ER) stress are the two
interrelated processes in cancer. ER stress induces CCAAT enhancer‐
binding proteins homologous protein (CHOP/GADD153), which is a key
proapoptotic factor (Min et al., 2012). ER stress also induces
p53‐upregulated modulator of apoptosis (PUMA). PUMA is a
p53‐dependent and ‐independent apoptosis mediator that directly
attaches and antagonizes all known antiapoptotic Bcl‐2 families.
Induction of PUMA by ER stress is p53‐independent (Yu & Zhang,
2009). There is a negative reciprocal feedback between CHOP and Bcl‐
2: with a rise in the expression of either one, a decrease in the level of
another will result (McCullough, Martindale, Klotz, Aw, & Holbrook,
2001; Oyadomari & Mori, 2004). CHOP, through increase of PUMA
expression in a p53‐independent manner, sensitizes cancer cells to
apoptosis (Um et al., 2011). The possible roles for combinational
melatonin therapy in ER stress‐mediated apoptosis are still controver-
sial. A highlight of most of the reports is a positive contribution for
combination therapy on apoptosis induction by ER (Fan, Sun et al., 2013;
Min et al., 2012; Zha et al., 2012), through which, melatonin increases
chemotherapy‐induced apoptosis (Fan, Sun et al., 2013). In one report,
however, no possible effect for melatonin combination on ER stress was
reported. Instead, the authors of this study found a role of the
antioxidative function of melatonin as a putative mediator of apoptosis
in cancer cells (Um & Kwon, 2010).
5 | OXIDATIVE STRESS
ROS induction in tumor cells is an interesting feature for the use of the
antioxidant melatonin (Y.‐X. Lu, Chen et al., 2016) in combination
therapies (Shen et al., 2017), which makes a distinction between this
hormone and other antioxidants, such as N‐acetyl‐L‐cysteine, showing
inhibitory effects on ROS production in cancer cells (Y.‐X. Lu, Chen et al.,
2016). Overproduction of intracellular ROS is usually associated with
apoptotic cell death (Pariente et al., 2016) and mitophagy (Shen et al.,
2017). It has been reported that early production of ROS is implicated in
the extrinsic apoptosis pathway (Casado‐Zapico et al., 2010), and it
seems that late ROS generation induces the mitochondrial pathway of
apoptosis (Pariente et al., 2016). With an excessive rise in the ROS
levels, mitochondrial dysfunction occurs. These damaged mitochondria
are further removed by mitophagy, resulting in reduced oxidative injury
(Shen et al., 2017).
A advantage of using melatonin in combination therapies is its
role in reduction of oxidative toxicity mediated by chemotherapeutic
agents on healthy organs (Sookprasert et al., 2014), and pushing
forward this oxidative injury specifically on cancer cells
(Casado‐Zapico et al., 2010; Prieto‐Domínguez et al., 2016).
However, this does not always happen because in HCC melatonin
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administration through reduction of cisplatin‐induced ROS over-
production could play a negative role by inhibiting apoptosis in
cancer cells (Bennukul, Numkliang, & Leardkamolkarn, 2014). For
cancer‐engaging bone, melatonin is the only inducer of intracellular
oxidation in cancer cells, and the role of chemotherapy is negligible
(Casado‐Zapico et al., 2010). However, in normal cells around tumor,
melatonin—through its ability to donate electron (R. J. Vijayalaxmi,
Reiter, Tan, Herman & Thomas, 2004)—suppresses ROS production
to prevent mitochondrial dysfunction (Song et al., 2012). This
defective mitochondrial dysfunction, if it occurs, could make a
vicious cycle for increasing the rate of further mutations in
mitochondrial DNA in favor of cancer progression (Song et al., 2012).
There are controversial issues regarding the possible effects of
melatonin dosage on oxidative stress in cancer cells. It has been
reported in a study that combination with low micromolar melatonin
concentrations (i.e., 50 and 150 µm) could reduce ROS generation in
cancer cells, while combination with a higher millimolar melatonin
concentration (1mM) could induce apoptosis through increase of ROS
production (Wenzel et al., 2005). However, in another report, reduction
of ROS levels in cancer cells was found after incubation of cancer cells
with a combination of chemotherapy and 1mMmelatonin. Interestingly,
in this study, a lower millimolar concentration for melatonin (i.e.,
0.5mM) showed a converse result through induction of ROS generation
in cancer cells (Shen et al., 2017). The types of chemotherapies used in
these studies were different (Bennukul et al., 2014; Prieto‐Domínguez
et al., 2016; Wenzel et al., 2005); so it is not unexpected to also add the
type of chemotherapeutic agent responsible for the changes caused by
melatonin on oxidative stress‐mediated apoptosis in cancer cells. As an
evidence for this claim, melatonin combination with cisplatin has been
reported to considerably induce ROS production, while combination
with 5‐FU moderately induces ROS generation (Pariente et al., 2016).
Therefore, the type of chemotherapy might be one of the criteria
needed to be considered for determination of the melatonin dosage.
The role of mitophagy is also needed to be considered. In the
beginning of mitophagy, there is a huge rise in the ROS. By contrast,
in late mitophagy, the ROS concentration is reduced (Shen et al.,
2017). This may be a possible reason for the two diverse findings
mentioned above regarding combination with 1mM melatonin.
Combination melatonin therapy, through both anti‐ and pro‐
oxidative functions, induces apoptosis in cancer cells. Melatonin
combination through inducing a pro‐oxidative milieu induces apop-
tosis in cancer cells (Wenzel et al., 2005). Simultaneously, melatonin
combination through inducing an antioxidative milieu induces ER
stress‐mediated apoptosis (Min et al., 2012). These two diverse roles
for melatonin are among other unique features for this versatile and
multitasking hormone, indicating the high compatibility of this
hormone for targeting human tumors.
6 | MOBILITY (MIGRATION)
Melatonin alone is not an appropriate option for targeting migration.
There is a shallow migratory response from cancer cells to just
melatonin therapy (J. Wang et al., 2013; Yi et al., 2014). The point in
this regard is that to reduce migration, melatonin is needed to be
administered at higher doses or higher incubation times than the
dose or time required for reduction of viability (Y.‐X. Lu, Chen et al.,
2016). When it is used in combination with chemotherapeutic agents,
melatonin could effectively reduce cancer cell migration (Gao et al.,
2017; J. Wang et al., 2013; Yi et al., 2014).
7 | CANCER CELL RESISTANCE
Cancer cell resistance is an important factor that generates complex
responses from cancer cells to chemotherapy, demanding higher
doses to exert optimistic effects (Fic et al., 2017). The existence of
MDR proteins in cancer cells is among these factors. P‐glycoprotein
(P‐gp) is an example of the proteins encoded by the ABCB1 gene (Fic
et al., 2017). P‐gp is expressed by mitochondria (Fantappiè et al.,
2015) and is located in the membranes of intracellular organelles and
in the nuclear envelope. Melatonin combination is promising for
reduction of P‐gp expression, but because of increasing ABCB1
mRNA expression and the fact that there is no report about the
possible effects of this combination therapy on ABCB1 protein and
activity, there is still a need for future research in this regard (Fic
et al., 2017). Other factors implicated in cancer cell resistance with
their possible functions are listed in Table 4.
8 | SOME CRITERIA NEEDED TO BE
CONSIDERED FOR IMPROVING
THERAPEUTIC EFFICACY USING
MELATONIN AS AN ADJUVANT FOR
CHEMOTHERAPY OF CANCER
These criteria are as follows:
(1) It is important to choose between either pre‐/co‐ or posttreat-
ment therapy of melatonin for targeting cancer chemotherapy.
For example, melatonin pretreatment, rather than cotreatment,
has been found to provide an appropriate combination with
chemotherapy for targeting breast cancer (Alonso‐González
et al., 2018; Granzotto et al., 2001). Melatonin pretreatment
has also been identified to induce cytocidal effects on cancer
cells, while melatonin posttreatment exerts cytostatic effects
(Eck et al., 1998).
(2) The time of melatonin administration is also important.
Melatonin is a chronobiotic hormone, and because some
tumors contain clock genes, the timing of prescription for this
indole possibly determines its therapeutic efficacy (Eck et al.,
1998). In addition, night‐time secretion for melatonin is
decreased in cancer patients (Kajdaniuk et al., 2001; Rodri-
guez‐Garcia et al., 2013), and there are no significant changes
in plasma melatonin concentration in these patients during the
morning time (Kajdaniuk et al., 2001). Moreover, despite its
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TABLE 4 Factors inducing chemoresistance in cancer cells
Factor name Function Evidence Ref.
HIF‐1 Mediator of invasion and vasculogenesis HCC Prieto‐Domínguez et al. (2017)
Chk1 and Chk2 Reduction of telomerase activity is related to apoptosis induction in
tumor cells
APL Koh et al. (2011)
Persistence of
telomerase activity
T790 is a type of EGFR that its mutation causes drug resistance Ovary Futagami et al. (2001)
EGFR mutation An example of MDR proteins encoded by the ABCB1 gene and
expressed in mitochondria
Lung Yun et al. (2014)
P‐gp An inducible type of cyclooxygenase, Colon Fic et al. (2017)
COX‐2 A proline‐directed serine/threonine kinase regulating cell
proliferation, apoptosis, DNA repair, metastasis and checkpoint
escape
HCC Fan, Song et al. (2013)
Cdk5 NF‐κβ is responsible for cancer cell resistance to apoptosis Breast NavaneethaKrishnan et al. (2018)
NF‐κβ GSH is involved in cancer cell survival and resistance to
chemagents
Prostate Rodriguez‐Garcia et al. (2013)
GSH IAPs are endogenous inhibitors of apoptosis via suppressing
caspases. Survivin is the smallest member of this family that
blocks apoptosis via both caspase‐dependent and caspase‐
independent mechanisms, and that its transcription is linked to
the overexpression of P‐gp
Prostate Rodriguez‐Garcia et al. (2013)
IAP Reduction of telomerase activity is related to apoptosis induction in
tumor cells
Prostate Rodriguez‐Garcia et al. (2013); S. Wang
et al. (2016)
Note. APL: acute promyelocytic leukemia; Cdk5: cyclin‐dependent kinase 5; COX‐2: cyclooxygenase‐2; EGFR: epidermal growth factor receptor;
HCC: hepatocellular carcinoma; IAP: inhibitors of apoptosis proteins; and MDR: multidrug resistance; NF‐κβ: nuclear factor kappa β; P‐gp: P‐glycoprotein.
F IGURE 1 Roles for combination of melatonin and chemotherapy for targeting human lung cancer. BBR: berberine; CHOP: CCAAT
enhancer‐binding proteins homologous protein; Cis: cisplatin; COX‐2: cyclooxygenase‐2;cyt‐c: cytochrome c; Dox: doxorubicin; EGFR:
epidermal growth factor receptor; EGFR: epidermal growth factor receptor; ER: endoplasmic reticulum; Gef: gefitinib; IP3R: inositol 1,4,
5‐trisphosphate receptor; MCU: mitochondrial Ca2+ uniporter; MMP: matrix metalloproteinase; MPTP: mitochondrial permeability transition
pore; PARP: poly ADP‐ribose polymerase; PI3K: phosphoinositide 3‐kinase
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F IGURE 2 Combination of melatonin with chemotherapy for targeting human ovary, squamous cell carcinoma (SCC), skin, and bone cancers.
5‐FU: 5‐fluorouracil; COX‐2: cyclooxygenase‐2; cyt‐c: cytochrome c; Fis: fiestin; HSP: heat shock protein; Ifos: ifosfamide; iNOS: inducible
nitric oxide synthase; MKP3: MAP kinase phosphatase 3; MPTP: mitochondrial permeability transition pore; PARP: poly ADP‐ribose
polymerase; Rap: rapamycin; Cis: cisplatin; Vin: vincristine
F IGURE 3 Combination of melatonin with chemotherapy for targeting human colon and cervical cancer. 5‐FU: 5‐Fluorouracil; Cis: cisplatin;
COX‐2: cyclooxygenase‐2. cyt‐c: cytochrome c; DOX: doxorubicin; DP: devazepide; FL: flavone; iNOS: inducible nitric oxide synthase;
LG: lorglumide; MPTP: mitochondrial permeability transition pore; OXA: oxaliplatin; PARP: poly ADP‐ribose polymerase; PDK1:
3‐phosphoinositide‐dependent protein kinase‐1; PG: proglumide; P‐gp: P‐glycoprotein; PI3K: phosphoinositide 3‐kinase; UA: ursolic acid
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safe application with no major adverse effects, some people
may experience sleepiness after melatonin prescription.
Therefore, melatonin is preferred to be administered during
evening (Mills, Wu, Seely, & Guyatt, 2005) or night (Cerea
et al., 2003) so as to maintain a physiological circadian rhythm
for this indole (Ghielmini et al., 1999) and not to cause
intolerance in patients.
(3) The duration of cancer cell exposure to melatonin is another
point needed to be considered. Because of the fact that cancer
cells promote resistance after melatonin withdrawal, continuous
exposure to melatonin is preferred (Lu, Chan et al., 2016).
(4) It is important to choosing pharmacological rather than
physiological concentrations for melatonin used in combina-
tion therapies. At pharmacological concentrations, melatonin
is an effective adjuvant for cancer chemotherapy, while at
physiological concentration, it is not so effective (Ju et al.,
2016). Physiological melatonin concentration exhibits cyto-
static activity in cancer cells, while pharmacological melatonin
concentrations evolve cytotoxic effects (Blask, Sauer, &
Dauchy, 2002). To play an antiproliferative role, melatonin is
needed to reach mitochondria (Shen et al., 2017), which might
seem to demand higher melatonin doses or increased time
exposure. Surprisingly, melatonin’s amphiphilic nature and its
small size are the two features that give melatonin a capacity
to easily reach all cellular and subcellular compartments
(Mortezaee, 2018; Paradies, Petrosillo, Paradies, Reiter, &
Ruggiero, 2010). Thus, low pharmacological concentrations are
required for melatonin to combat cancer cell progression. This
is probably work‐full for low‐grade cancers. High‐grade
tumors, however, need an increase in melatonin dosage so as
to improve quality of life in patients (Sookprasert et al., 2014).
It is worth noting that the number of passages for cancer cells
influences the dosage of melatonin needed for using in
combination therapy of cancer in which with an increase in
the number of passages for cancer cells, the need for
increasing the dosage for melatonin will rise, and vice versa
(Rodriguez‐Garcia et al., 2013). This is important when we are
trying to find the correct dosage for melatonin in cancer‐
targeted therapies. Another important factor that influences
the dose for melatonin is the age of the patients, in which
patients above 50 years of age experience a considerable
reduction in plasma melatonin levels (Radio, Doctor, & Witt‐
Enderby, 2006), demanding higher doses.
(5) Maintaining darkness during night times for patients receiving
cancer adjuvant therapy with melatonin. Exposure to light during
night perturbs melatonin interactions with tumor cells; and
nocturnal reduction of melatonin levels correlates directly with
the tumor size (Vijayalaxmi et al., 2002).
(6) Identifying whether cancer cells are resistant or not to
chemotherapy. As expected, melatonin combination is more
effective for cancer cells that are resistant to chemotherapy (Fic
et al., 2017; Granzotto et al., 2001; Ju et al., 2016).
F IGURE 4 Combination of melatonin with chemotherapy for targeting human breast, blood, and renal cancer. Cdk5: Cyclin‐dependent
kinase 5; CHOP: CCAAT enhancer‐binding proteins homologous protein; cyt‐c: cytochrome c; DTX: docetaxel; IP3R: inositol 1,4,5‐trisphosphate
receptor; Kah: kahweol; MCU: mitochondrial Ca2+ uniporter; MPTP: mitochondrial permeability transition pore; OXA: oxaliplatin; PARP: poly
ADP‐ribose polymerase; PPARγ: peroxisome proliferator activated receptor γ; PUMA: p53‐upregulated modulator of apoptosis;
Pur: puromycin; TGZ: troglitazone
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9 | CONCLUSION AND PERSPECTIVE
From all that has been discussed here, it could be concluded that
combination with melatonin is a promising approach for targeting
cancer. There is even evidence for complete response from some
types of cancers in clinic to this combination therapy, for low‐
(Todisco, 2007) and high‐grade (Todisco, 2006) non‐Hodgkin
lymphoma, and for a number of patients suffering from gastro-
intestinal tumors, breast cancer, NSCLC, and head and neck cancer
(Lissoni, Barni et al., 1999). In the Figures , the mechanisms for
combination melatonin therapy have been shown differentially for
cancer cells, and in the Table 1, proper dosage and incubation time
used, specifically for cancer cells, have been highlighted.
Combination therapy with melatonin has advantages in numerous
aspects as follows: (a) abrogating chemotherapy stimulatory effect on
cytosolic oxidation in favor of ER stress‐mediated apoptosis induction
in cancer cells (Min et al., 2012); (b) modulation of cell cycle as well as
multiple signal transductions related to cancer cell survival; (c)
reduction in the dosage of chemotherapy drug needed to exert
cytotoxic effects (Casado‐Zapico et al., 2010); (d) increase of the
overall rate for tumor regression (Lissoni, 2007; Lissoni et al., 2003);
(e) reduction of chemotherapy‐related side effects to normal cells (Y.
Wang et al., 2012) and tissues (Lissoni, Barni et al., 1999; Shen et al.,
2017); (f) removal of cancer cell resistance to chemotherapy (Shen
et al., 2017); (g) modulation of the changes induced by chemotherapy
in gene expression profiles (Alonso‐González et al., 2018); (h)
attenuation of cancer cell migration; (i) extending the time required
for cancer progression (Lissoni, Barni et al., 1999), resulting in an
increase in patient survival; (j) preventing chemotherapy‐mediated
immunosuppression (Lissoni, Barni et al., 1999); (k) exerting cytocidal
effects on cancer cells (Eck et al., 1998) rather than cytostatic effects
exerted by hormonal administration alone (Sainz et al., 2003); (l)
reduction of cancer cell resistance factors induced by chemotherapy
agents on cancer cells (Rodriguez‐Garcia et al., 2013); and (m)
reversing the adverse effects of cancer cells on other systems
(Lissoni, Tancini et al., 1999; Lissoni et al., 2001).
Among the benefits of melatonin application, there is a great
advantage in that this hormone exerts no hazardous effects on normal
cells, while it is highly capable of targeting cancer cells, especially in
combination with chemotherapeutic agents. One reason is the re‐
establishment in the dark/light circadian rhythm. This is essential for
normal cell growth. During cancer progression, there is a reduction in
the concentration of melatonin (as discussed earlier) probably because
of the reduced activity of the pineal gland. When melatonin is
administered exogenously, it could restart or potentiate its beneficial
outcomes on normal cells by modulating this rhythmicity. Another
reason is that melatonin can maintain a balance in intracellular redox
system for normal cells. To do this, melatonin easily penetrates from
plasma membrane to the cytosol because of its amphiphilic nature and
its small size (Mortezaee, 2018). For cancers, this function is reversed,
where melatonin disrupts the redoxing system for cancer cells to retard
their growth. To explain, cancer stem cells and bulk cancer cells are
highly vulnerable to any changes in their intracellular redox state (C. Lu,
Laws, Eskandari, & Suntharalingam, 2017). This vulnerability is
dependent on the ROS concentration to a great extent. A high
concentration of ROS could be therapeutic through inducing apoptotic
mediators. In contrast, activation of antioxidative enzymes after
attenuation of intracellular ROS levels could be a promoter of cancer
cell proliferation (Mortezaee, 2018). Cancer cells are highly capable of
maintain a redox balance for attaining progressive related features.
These cells also have high rates of oxidative stress as well as increased
activity of antioxidative related enzymes (Kong & Chandel, 2018). When
the rate of ROS production in the cells reached an undesired state,
antioxidative machinery is activated to keep the cells in a proactive
position. Therefore, having high capability for both oxidative and
antioxidative machinery in cancer cells and sophisticated mechanisms
over maintaining a balance between the two phenomenon has made
cancer cells easily adopt to new environments for promotion of tumor
growth (Qiao et al., 2018; Tsang et al., 2018). The role for melatonin
here is to reduce the load of ROS on normal cells, instead, pushing this
load toward cancer cells. This is important for retarding cancer growth
because when normal cells are loaded by ROS, the cells promote
mitochondrial dysfunctions that further increase mutations in mito-
chondrial DNA in a vicious cycle favoring cancer progression in normal
cells (Song et al., 2012). For retarding cancer cell growth, by contrast,
melatonin adopts an interesting mechanism through its pro‐oxidative
and antioxidative potentials to induce apoptosis in cancer cells. Recall,
that its pro‐oxidative feature on cancer cells suppressess antiapoptotic
mediators and releases cytochrome c, subsequent activating caspase
cascades (Mortezaee, 2018). Besides, melatonin, through its antioxida-
tive activity, could induce ER stress‐mediated apoptosis (mentioned
earlier). These functions are potentiated when melatonin is adminis-
tered in combination with chemotherapeutic agents. Taking these
results together, it could be speculated that melatonin, through its
selective targeting ability, could exert its therapeutic potential with high
efficacy, and combinational application is for applying cumulative
therapeutic outcomes on cancer cells and for reducing adverse effects
on normal cells.
Beside these pros for the adjuvant therapy, melatonin
combination negatively affects DNA repair in normal cells, such
as healthy lymphocytes in cancer patients (Kontek & Nowicka,
2013). Unrepaired double‐DNA strand breaks (DSBs) results in cell
apoptosis, while misrepaired DSBs leads to cell transformation
into cancer (Kontek & Nowicka, 2013). In addition, melatonin also
increases GSH in cancer cells (Rodriguez‐Garcia et al., 2013),
which contributes to cancer cell survival as well as its resistance to
chemotherapeutic agents (Fojo & Bates, 2003; Rodriguez‐Garcia
et al., 2013). So, it is speculated that melatonin sometimes may
even induce resistance to chemotherapeutic agents. However, the
more effective melatonin combination for cancer cells resistant to
chemotherapy (Fic et al., 2017; Granzotto et al., 2001; Ju et al.,
2016) and reduction of cancer cell resistance factors induced by
chemotherapy agents on cancer cells (Rodriguez‐Garcia et al.,
2013) are among possible reasons against the mentioned
speculation for this hormone. In addition, it has been reported
that melatonin‐mediated cancer resistance probably occurs for
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irritation not for chemotherapy (Rodriguez‐Garcia et al., 2013).
Finally, to exert an appropriate influence over GSH, modulation of
concentration for this highly versatile hormone is required
(Osseni, Rat, Bogdan, Warnet, & Touitou, 2000).
Investigations into knowing more about using melatonin in combina-
tion with chemotherapy are underway, because no direct consensus
about some functions for this hormone exists. For instance, considering
the roles of melatonin against chemotherapy‐mediated myelotoxicity,
positive retardation by melatonin in one report (Lissoni, Tancini et al.,
1997), but no protective role for this hormone in another report has
been concluded (Ghielmini et al., 1999). In addition, the effects of
combinational melatonin therapy on cell cycle are controversial. As an
example, melatonin combination exerts roles as an inducer (Fan, Sun
et al., 2013; Koh et al., 2011; Zha et al., 2012), a suppressor (Bennukul
et al., 2014), or even no effect (Pariente, Bejarano, Rodríguez et al., 2017)
on cell cycle arrest in the sub‐G1 phase. These diversities demand future
investigations, in the hope to reach a milestone for combating cancer in
society. There also unknown features regarding possible contributions
for combination melatonin in angiogenesis and invasion of cancer cells,
highly demanding future studies.
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